Navigation Links
Reportlinker Adds Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2011

NEW YORK, April 27, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2011


Following the example of the US FDA's Orphan Drug Act established in 1983, some Asian countries have developed orphan drug legislations, such as Singapore's Orphan Drug Exemption to the Medicines Act and Japan's Orphan Drug Amendment to the Pharmaceutical Affairs Law.

While orphan drug laws in Asia may provide benefits for companies registering new drugs, such as marketing exclusivity, an expedited registration process, and a reduction in the number of clinical trials required, each registration process is unique and can pose a variety of challenges.

This report reviews the orphan drug regulations in 10 Asian countries and discusses various business issues related to orphan drugs in the region. Lists of approved orphan drugs in Japan and Korea as well as a list of orphan drug associations are also included.

Updates for 2011 include:

• Recent 2011 government approval list for orphans drugs in the US and Japan

• Recent issues surrounding rare disease treatment in 10 Asian countries

• Latest orphan drug registration policies and regulations in Asia

This report is 109 pages.


I. Introduction 

A. Global Outlook on rare diseases

B. Development of Orphan Drug Legislation

C. Well-Known Rare Diseases

D. US FDA Contact Information

E. US Orphan Drug Associations

F. US FDA Orphan Drug Approvals

II. Overview of Asia 

A. The Asian Economy

B. The Pharmaceutical Markets in Asia

III. Orphan Drugs in Asia 

A. Do orphan drugs have potential in Asia?

B. Why seek orphan drug status?

IV. Issues to Consider Prior to Orphan Drug Registration 

A. Introduction

B. Are treatment options already available in the country?

C. Is your drug superior to those already on the market?

D. Conclusion

V. Japan 

A. Introduction

B. Ministry of Health, Labor and Welfare

C. Pharmaceuticals and Medical Devices Agency

D. Orphan Drugs in Japan

E. Health Authority Contact Information

F. Orphan Drug Associations

G. Orphan Drugs Approved in Japan

H. Orphan Drugs Designated in Japan

VI. Taiwan 

A. Overview

B. Taiwanese Health Authorities

C. Health Insurance Scheme

D. Orphan Drugs in Taiwan

E. Health Authority Contact Information

F. Orphan Drug Associations

VII. Korea 

A. Overview

B. Drug Registration Overview

C. Orphan Drugs in Korea

D. Health Authority Contact Information

E. Orphan Drug Associations

F. Orphan Drugs Approved in Korea

VIII. Hong Kong 

A. Overview

B. Hong Kong Health Authority

C. Orphan Drugs In Hong Kong

D. Health Authority Contact Information

IX. China 

A. Overview

B. Pharmaceutical Market

C. China Health Authority

D. Drug Registration Process

E. Drug Pricing

F. Orphan Drugs in China

G. Health Authority Contact Information

X. Singapore 

A. Overview

B. Singapore Health Authority

C. Orphan Drug Definition and Legislation

D. Health Authority Contact Information

XI. Southeast Asia Introduction 

A. Overview

B. Drug Registration Requirements for Southeast Asia

XII. Philippines 

A. Overview

B. Philippines Health Authority

C. Orphan Drug Registration Process

D. Health Authority Contact Information

XIII. Malaysia 

A. Overview

B. Malaysia Health Authority

C. Drug Registration Overview

D. Health Authority Contact Information

XIV. Thailand 

A. Overview

B. Drug Registration Overview

C. Orphan Drug Summary

D. Health Authority Contact Information

XV. Vietnam 

A. Overview

B. Drug Registration Overview

C. Health Authority Contact Information

D. Orphan Drug Associations

XVI. Sales and Marketing of Orphan Drugs 

A. Introduction

B. Preparing a Sales Forecast

C. In-country Support

D. Distribution

XVII. Conclusion

To order this report:

: Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2011

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Epidemiology: Sepsis
2. Reportlinker Adds Cancer Vaccines Markets
3. Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
4. Reportlinker Adds Epidemiology: Rheumatoid Arthritis
5. Reportlinker Adds Epidemiology: Multiple Sclerosis
6. Reportlinker Adds Epidemiology: Lupus
7. Reportlinker Adds Epidemiology: Prostate Cancer
8. Reportlinker Adds Medical Equipment Monthly Deals Analysis - M&A and Investment Trends, April 2011
9. Reportlinker Adds Body Contouring Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Reportlinker Adds Ophthalmology DrugFutures
11. Reportlinker Adds Europe ENT Devices Market Outlook to 2017
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):